0.35Open0.70Pre Close3 Volume1.28K Open Interest5.00Strike Price105.00Turnover96.23%IV5.68%PremiumJan 17, 2025Expiry Date0.11Intrinsic Value100Multiplier9DDays to Expiry0.29Extrinsic Value100Contract SizeAmericanOptions Type0.5890Delta0.4885Gamma13.63Leverage Ratio-0.0169Theta0.0007Rho8.03Eff Leverage0.0032Vega
Aldeyra Therapeutics Stock Discussion
Larger Image: tradingview.com...
$Aldeyra Therapeutics (ALDX.US)$
NEWS
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Positive
Enrollment of the first patient in the Phase 3 clinical trial for reproxalap indicates progress in Aldeyra Therapeutics' efforts to address dry eye disease.
Potential resubmission of the NDA for reproxalap in the second half of 2024 demonstrates the company's commitment to advancing in...
No comment yet